Apellis Pharmaceuticals: cross-border access for the specialty portfolio

Quick orientation

Apellis Pharmaceuticals, Inc. is a US biopharmaceutical company headquartered in Waltham, Massachusetts, focused on complement-targeted therapeutics. Apellis developed the first commercially approved C3 complement inhibitor and is commercialising it across ophthalmology (geographic atrophy) and hematology (paroxysmal nocturnal hemoglobinuria). The company trades on NASDAQ as APLS. FDA approval scale is two marketed products that share the same molecule (pegcetacoplan) in different formulations and indications, with additional indications and combinations in active development.

Apellis portfolio in cross-border NPP scope

Syfovre (pegcetacoplan injection) is an FDA-approved intravitreal injection for geographic atrophy (GA) secondary to age-related macular degeneration (FDA approval February 2023). Syfovre is the first FDA-approved therapy for GA, a chronic progressive form of advanced dry AMD that causes irreversible vision loss. Intravitreal administration every 25 to 60 days by a retinal specialist. US list pricing is approximately US$2,200 per injection; total annual cost depends on dosing frequency. The product is supplied as a single-use vial requiring cold-chain handling.

Empaveli (pegcetacoplan) is an FDA-approved subcutaneous infusion C3 complement inhibitor for adults with paroxysmal nocturnal hemoglobinuria (PNH), approved by the FDA in May 2021. Empaveli is delivered as twice-weekly subcutaneous infusion via an infusion pump. US list pricing is in the range of US$50,000 per month at the labeled dose. Refrigerated cold-chain handling required.

Apellis pipeline includes pegcetacoplan in development for additional complement-mediated conditions including C3 glomerulopathy and IgA nephropathy. These are investigational and not in NPP scope.

Why patients route through cross-border NPP

Geographic atrophy is a major unmet need in ophthalmology globally. The condition affects approximately five million people worldwide and progressively destroys retinal photoreceptors and retinal pigment epithelium, leading to central vision loss. Until Syfovre's 2023 approval, no pharmacological therapy existed for GA. Outside the United States, Syfovre approval is uneven: the European Commission declined the marketing authorisation in March 2024, citing efficacy uncertainty, and the company is pursuing additional regulatory engagement. Many regulatory authorities in the GCC, India, and other markets are awaiting additional data or alternative regulatory pathways. Patients with confirmed GA by fundus autofluorescence imaging and treating-retina-specialist prescription routinely seek cross-border NPP supply where local options are unavailable.

Empaveli for PNH addresses a separate ultra-rare hematology population. PNH affects approximately one to five per million population globally, and historical first-line therapy has been C5 complement inhibitors (eculizumab, ravulizumab). Empaveli's C3 mechanism is differentiated and may benefit patients with persistent extravascular hemolysis on C5 inhibitors. Confirmed-PNH patients in jurisdictions where Empaveli is not commercially available route through cross-border NPP. Patient profile typically requires confirmed PNH by flow cytometry (GPI-anchored protein deficiency), treating-hematologist prescription, and infusion-pump capability locally.

Common cross-border destinations

The highest-frequency NPP destinations for Apellis products from US-approved inventory are the United Arab Emirates, Saudi Arabia, India, Qatar, and Turkey. Retina specialty centers for Syfovre and hematology centers for Empaveli in Dubai, Abu Dhabi, Riyadh, Mumbai, Bangalore, Hyderabad, Doha, and Istanbul drive most inbound referrals.

Manufacturer engagement posture

Reserve Meds coordinates Apellis-sourced US commercial product through DSCSA-compliant US specialty distributors. We are not affiliated with Apellis Pharmaceuticals. Our role is patient-facing coordination on behalf of named individual patients with a verified prescription. For Apellis medical affairs or commercial teams interested in cross-border NPP pathways, our BD contact is [email protected].

What Reserve Meds provides

For each Apellis product request, Reserve Meds coordinates: prescription verification with the treating physician (retinal specialist for Syfovre; hematologist for Empaveli); diagnostic documentation review (fundus autofluorescence or OCT imaging for GA; flow cytometry for PNH); DSCSA serialized chain-of-custody from Apellis through licensed US wholesalers to the named patient; refrigerated cold-chain shipping (2 to 8 degrees C) with temperature data-loggers; destination-country regulatory documentation for Ministry of Health named-patient approvals and customs clearance; and a dedicated coordinator from prescription to delivery.

Clinical governance and prescription review

Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.

Supply chain integrity

Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.

Destination-country regulatory pathways

Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.

What to expect through the coordination process

Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.

Not affiliated with the manufacturer

Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.

Privacy and data handling

Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.

Next step for patients

Patients with a treating-physician prescription for an Apellis product can begin a request now. Start a Syfovre request ›

Next step for Apellis teams

Apellis Pharmaceuticals medical affairs or commercial teams interested in cross-border NPP coordination for non-US territories can reach our BD team at [email protected].

Reserved for you.